当前位置:首页 - 行情中心 - 之江生物(688317) - 财务分析 - 现金流量表

之江生物

(688317)

  

流通市值:30.87亿  总市值:30.87亿
流通股本:1.90亿   总股本:1.90亿

现金流量表

报告期2026-06-302026-03-312025-12-312025-09-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金61,699,554.2930,131,909.48159,107,518.57120,213,144.22
  收到的税费返还-56,112.4830,093,967.9-
  收到其他与经营活动有关的现金32,280,061.0510,863,778.2369,655,823.5251,878,128.13
  经营活动现金流入小计93,979,615.3441,051,800.19258,857,309.99172,091,272.35
  购买商品、接受劳务支付的现金7,535,441.753,351,833.9829,720,255.7817,018,580.48
  支付给职工以及为职工支付的现金39,355,403.5921,885,869.8174,016,837.2357,114,359.51
  支付的各项税费9,534,158.555,309,364.3717,916,785.5413,908,036.03
  支付其他与经营活动有关的现金25,950,404.2814,164,472.9470,349,999.7351,377,879.66
  经营活动现金流出小计82,375,408.1744,711,541.1192,003,878.28139,418,855.68
  经营活动产生的现金流量净额11,604,207.17-3,659,740.9166,853,431.7132,672,416.67
二、投资活动产生的现金流量:
  收回投资收到的现金1,131,123,114.29263,513,630.781,117,230,829.5694,998,538.3
  取得投资收益收到的现金458,191.77---
  处置固定资产、无形资产和其他长期资产收回的现金净额--626,093.48340,000
  投资活动现金流入小计1,131,581,306.06263,513,630.781,117,856,922.98695,338,538.3
  购建固定资产、无形资产和其他长期资产支付的现金23,208,23722,378,976.91,994,776.173,068,392.5
  投资支付的现金1,138,165,294330,165,2941,422,586,455.161,011,507,951.71
  投资活动现金流出小计1,161,373,531352,544,270.91,424,581,231.331,014,576,344.21
  投资活动产生的现金流量净额-29,792,224.94-89,030,640.12-306,724,308.35-319,237,805.91
三、筹资活动产生的现金流量:
  取得借款收到的现金0-297,000,000198,000,000
  筹资活动现金流入平衡项目0-00
  筹资活动现金流入小计0-297,000,000198,000,000
  偿还债务支付的现金3,960,0001,980,0002,980,0001,980,000
  分配股利、利润或偿付利息支付的现金3,754,043.51,368,1013,032,195.551,840,803.25
  支付其他与筹资活动有关的现金44,820,648.2218,882,804.94261,344,830.68221,026,950.57
  筹资活动现金流出小计52,534,691.7222,230,905.94267,357,026.23224,847,753.82
  筹资活动产生的现金流量净额-52,534,691.72-22,230,905.9429,642,973.77-26,847,753.82
四、汇率变动对现金及现金等价物的影响-30,645,147.64-15,069,979.84-23,008,255.17-9,676,055.88
五、现金及现金等价物净增加额-101,367,857.13-129,991,266.81-233,236,158.04-323,089,198.94
  加:期初现金及现金等价物余额2,549,940,055.222,552,732,482.862,783,176,213.262,783,392,638.52
  期末现金及现金等价物余额2,448,572,198.092,422,741,216.052,549,940,055.222,460,303,439.58
补充资料:
  净利润-40,589,405.04--34,297,566.55-
  资产减值准备686,248.21--10,775,110.55-
  固定资产和投资性房地产折旧25,670,236.9-63,132,830.2-
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧25,670,236.9-63,132,830.2-
  无形资产摊销576,182.16-1,112,863.26-
  长期待摊费用摊销338,614.55-1,020,612.94-
  处置固定资产、无形资产和其他长期资产的损失530,902.52--44,975.63-
  固定资产报废损失--426,420.48-
  公允价值变动损失-1,443,309.15--2,360,210.85-
  财务费用36,228,915.13-26,139,406.12-
  投资损失-2,445,020.94--3,821,335.22-
  递延所得税-787,028.53--7,927,856.85-
  其中:递延所得税资产减少-787,028.53--7,927,856.85-
    递延所得税负债增加0---
  存货的减少10,420,414.96-10,509,555.31-
  经营性应收项目的减少-942,131.85-27,877,888.39-
  经营性应付项目的增加-13,208,944.49--10,979,555.71-
  其他-2,324,591.12-730,231.08-
  不涉及现金收支的投资和筹资活动金额其他项目--2,037,275.84-
  现金的期末余额2,448,572,198.09-2,549,940,055.22-
  减:现金的期初余额2,549,940,055.22-2,783,176,213.26-
  现金及现金等价物的净增加额-101,367,857.13--233,236,158.04-
公告日期2026-08-282026-04-302026-04-242025-10-30
审计意见(境内)标准无保留意见
TOP↑